Trial Profile
A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biogen Idec
- 01 Jun 2017 Results published in the Neurology and Therapy
- 19 Feb 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
- 23 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.